Canine spontaneous melanoma is a highly aggressive tumor resistant to current therapies. We evaluated the safety, efficacy and antitumor effects of direct intratumor injections of lipoplexes encoding herpes simplex thymidine kinase coadministrated with ganciclovir, and irradiated transgenic xenogeneic cells secreting 20-30 mg day À1 of human granulocyte-macrophage colonystimulating factor and interleukin-2. Toxicity was minimal or absent in all patients. This combined treatment (CT) induced tumor regression and a pronounced immune cell infiltration. The objective responses (47%: 21/45) averaged 80% of tumor mass loss. Local CT also induced systemic antitumor response evidenced by complete remission of one pulmonary metastasis and by the significantly higher percentage of metastasis-free patients (76: 34/45)) until the study ending compared to untreated (UC: 29%, 5/17), surgery-treated (CX: 48%, 11/23) or suicide gene-treated controls (SG: 56%, 9/16) (Fisher's exact test). CT significantly improved median survival time: 160 (57-509) days compared to UC (69 (10-169)), or 
Introduction
Spontaneous cancer models in companion animals offer an opportunity to develop preclinical cancer treatment trials. Beyond the advantage of working with larger animal models, provided by pet dog cancers, the similarities in tumor biology seen between specific human and canine cancers further contribute to their value as models of human cancer. 1 Naturally occurring melanoma in dogs develop twice as frequently as in man, displaying similar histopathological features and biological behavior but a progress faster on. Like human melanoma, the prognosis for canine malignant melanoma correlates directly with tumor stage. 2, 3 At the time of diagnosis, the disease is habitually metastatic and has an extremely poor prognosis. All the efforts of conventional treatments including extended resection, radiation, chemotherapy and conventional biological response modifiers such as Bacille Calmette-Gue´rin or Corynebacterium parvum extracts, have little influence on patients, survival. 4 Different gene therapy approaches have been reported for canine spontaneous melanoma, such as (i) xenogeneic ex vivo-generated interleukin-2 (IL-2)-producing engineered cells, 5 (ii) ex vivo-generated granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing autologous tumor cells, 6 (iii) in vivo enterotoxin-B plus IL-2 or GM-CSF gene transfer, 4 (iv) in vivo xenogeneic human tyrosinase gene transfer 7 and (v) in vivo human FasL gene transfer. 8 The current study describes a combination of suicide gene therapy and immunotherapy in dogs bearing malignant melanoma, as an alternative strategy to circumvent tumor-mediated tolerance and immunosuppression, inducing, at the same time, systemic antitumor immunity.
In vivo intratumor injections of lipid-complexed plasmid DNA 9 encoding the herpes simplex thymidine kinase suicide gene (SG) should sensitize transfected cells to ganciclovir. 10, 11 Due to the bystander effect, this SG-triggered cytotoxic effect allows substantial tumor regression by transfection of only a minority of tumor cells. 11, 12 In addition, this SG therapy strategy would let the release of previously unrecognized tumor antigens by cell lysis, facilitating antigen recognition following processing and presentation by professional antigen-presenting cells. On the other hand, cationic liposomes are among the most attractive vectors for gene therapy, because they are non-infective, have low toxicity, and high stability, and are not expensive to manufacture. In addition, plasmid DNA is relatively inexpensive and simple to purify in large quantities. 13 As a coadjuvant of SG therapy and to boost the antimelanoma immune response, we coadministrated irradiated xenogeneic cells genetically modified to secrete human IL-2 (hIL-2) and GM-CSF (hGM-CSF) at the tumor area. Histo-incompatible xenogeneic cells could break the state of relative immune tolerance and promote a strong immune response against a broader array of tumor antigens that lead to tumor growth inhibition or rejection.
14 Repeated induction of a potent local immune stimulus by xeno-antigens and local secretion of hIL-2 and hGM-CSF by xenogeneic cells, the most potent cytokines able to induce locoregional tumor rejection and tumor-specific systemic immunity, respectively, would elicit a powerful antitumor synergy that delays or prevents recurrence and metastasis. [15] [16] [17] [18] [19] In a murine model of colon cancer hepatic metastases treated with SG, IL-2 and GM-CSF, it was demonstrated that GM-CSF is essential for augmenting tumor cell infiltration by dendritic cells, macrophages and tumor-infiltrating lymphocytes. 20 The effectiveness of this combination was also demonstrated for murine colon cancer, 21 melanoma, 22 gastric 23 and breast cancer. 24, 25 Therefore, repeated injections of both SG system and cytokine-secreting xenogeneic cells into the tumor bed could be a powerful strategy to prevent relapse and thus support a longer immune response with a stronger antitumor memory.
Both hIL-2 and hGM-CSF successfully displayed crossspecies biological activity, 5, 6 and their use can simultaneously serve both as a preclinical safety assay and as a proof of concept for forthcoming human gene therapy trials.
We present data suggesting that this combined treatment could substantially control tumor growth, delay or prevent distant metastasis and significantly extend survival rate, with a consequent improvement of the patient's quality of life.
Materials and methods

Cells
Two engineered Chinese hamster ovary cell lines (CHO-K1, ATCC no. CCL 61) daily producing about 200 ng of hIL-2 per 10 6 cells and 1500 ng of GM-CSF per 10 6 cells, respectively, were obtained in our laboratory by using a dhfr-driven gene amplification as described previously. 26, 27 Cells were cultured in T175 flasks at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 with IMDM/F12 medium (Hyclone, Logan, UT) containing 10% fetal bovine serum (Natocor, Co´rdoba, Argentina), 10 mM HEPES (pH 7.4), 2 mM L-glutamine and antibiotics. Serial passages were performed by trypsinization (0.25% trypsin and 0.02% EDTA in PBS) of subconfluent monolayers. Before inoculation, cells were exposed to g-rays (5000 rad).
Quality assessment of the cytokine-producing cells comprised determination of in vitro expression levels by ELISA, in vitro biological proliferation assays in the presence of cells secreted molecules, in vivo cytokine plasma expression by subcutaneous injection in Balb/c mice and mycoplasma control.
ELISA assay
Recombinant hGM-CSF and hIL-2 released to the culture medium were quantified by ELISA kit method as described by the manufacturer (R&D Systems, Minneapolis, MN). Cytokine production was expressed as ng per 10 À6 cells per day, as means ± s.e.m. determined in triplicate.
Plasmids psCMVtk (4.5 kb) carries an EcoRI/BglII fragment (1.2 kb) containing HSVtk gene, cloned in the sites EcoRI/BamH1 of psCMV (3.3 kb) downstream of the CMV promoter and upstream of poly A sequences, and the kanamycin-resistance gene for selection in Escherichia coli.
hIL-2 and hGM-CSF genes were subcloned under the CMV promoter of pRc/CMV (Invitrogen, Carlsbad, CA) as described previously. 27 Plasmids were amplified in E. coli DH5a (Invitrogen) grown in Luria-Bertani medium containing 100 mg ml À1 neomycin and purified using an ion-exchange chromatographic method (Qiagen, Valencia, CA). Plasmid DNA for injection was resuspended to a final concentration of 2.0 mg ml À1 in sterile PBS. Quality assessment comprised plasmid supercoiling checking by agarose gel electrophoresis, restriction enzyme mapping, in vitro lipofection of cultured cells and efficacy of the HSVtk/ganciclovir (GCV) system. 28 Liposome preparation and in vivo lipofection DMRIE (1,2-dimyristyl oxypropyl-3-dimethyl-hydroxyethylmonium bromide) 28 was synthesized and kindly provided by Bio Sidus S.A. (Buenos Aires, Argentina). DOPE (1,2-dioleoyl-sn-glycero-3-phosphatidyl ethanolamine) was purchased from Sigma (St Louis, MO). Liposomes for injection were prepared by combining equimolar amounts of DMRIE and DOPE. Lipids in chloroform solution were evaporated to dryness, and liposomes were prepared by reconstitution in sterile Na 2 HPO 4 /NaH 2 PO 4 0.1 M (pH 7.3) to a final concentration of 1.0 mg ml À1 , followed by 10 cycles of 15 s sonication at 4 1C. 27, 29 Before injection, liposomes and plasmid DNA (1:2, v:v) were mixed and allowed to complex at room temperature for 10 min. GCV (5 mg mg À1 DNA) was then added and lipoplexes were injected as described below. 9 Patients Dogs included in this study had confirmed histopathological diagnosis of melanoma. The tumors were staged by a veterinary oncologist according to the WHO staging system of stage II (tumors 2-4 cm diameter, negative nodes), stage III (tumor 44 cm and/or positive lymph nodes) or stage IV (distant metastatic disease). All dogs were determined to be free of underlying severe systemic illnesses. During the study, dogs did not receive chemotherapy or another potentially antitumor medication. The dogs' owners were notified about the experimental nature of the treatment and all of them granted written informed consent for treatment.
Treatment
Patients that received the combined treatment (n ¼ 45) were injected weekly for 5 weeks intra and peri-tumorally at multiple sites with (i) lipid-complexed plasmid DNA encoding HSVtk (1-4 mg DNA co-delivered with 5-20 mg GCV according to the tumor size) and (ii) coadministrated with irradiated xenogeneic cells genetically modified to secrete both hGM-CSF (20-30 mg) and hIL-2 (20-30 mg). At this point, patients followed the previous scheme less frequently: every 14, 28 or 56 days. Tumors were treated until they resolved or were judged to be unresponsive. After 24 and 48 h following intratumor injections, patients orally took 400-800 mg of acyclovir according to their weight.
Periodic clinical evaluations were performed on every treatment day and were completed by monthly or bimonthly clinical laboratory analysis. Thoracic radiographs, abdominal echographs and histological follow-up were done before treatment and every month according to the patients response, and at longer intervals in long-term surviving animals. During treatment, dogs were monitored for changes in attitude, appetite, body temperature, body weight and tumor appearance. Data about combined treatment efficacy and toxicity (n ¼ 45) were compared to control patients untreated (n ¼ 17), subjected only to surgery (n ¼ 23) or subjected only to suicide gene system (n ¼ 16).
Tumor response criteria Tumor responses, evaluated by caliper measurement of tumor 3 diameters (V ¼ 4/3pr 1 r 2 r 3 ), were classified as follows: complete remission, macroscopic disappearance of the tumor; partial remission, reduction of tumor size higher than 50%; stable disease, stabilization or increase in tumor size o50%; progressive disease, increase of tumor size 450%. Assessment of clinical response considered all measurable lesions.
Histology
For histopathological examination, tumor biopsies were placed in 10% formaldehyde, embedded in paraffin and sliced in 5-mm sections for hematoxylin/eosin staining.
Quality of life
Evaluation was based on the owner's response to a questionnaire completed before every treatment session. The answers about the different aspects were scored: 1 ¼ worse, 2 ¼ no change and 3 ¼ better compared to the predisease state. For the sake of simplicity, values scored 2 or 3 were considered as a positive effect on the quality of life.
Statistics
Disease-free, metastasis-free and overall median survival were calculated by Kaplan-Meier analysis, and curves were compared by log-rank test. Response values were compared by Fisher's exact test. Mean size modifications of tumors after local treatment were analyzed by ANOVA test.
Results and discussion
This study proposes that spontaneous canine cancers can serve as a valuable bridge between preclinical studies and human clinical trials, to decrease the use of experimental laboratory animals, and provides additional rationale for the use of the dog model for human melanoma.
Canine malignant melanoma is a spontaneous syngeneic cancer occurring in outbred, immune-competent large mammals that live in the same environment that humans do, constituting a more clinically faithful therapeutic model for human melanoma when compared with the more traditional mouse/rat systems. 1 In general, clinical trials using veterinary patients can be completed in onefifth of the time (1-3 years) at significantly lower expense than similar human clinical trials. With a potentially large population of cases for investigation, time course is long enough to allow comparison of response times but short enough to ensure rapid collection of data. 1 
Patient demographics
Patients untreated or treated with surgery, suicide gene alone or combined with cytokine-secreting xenogeneic cells had respective median ages of 13, 11, 13 and 13 years and were predominantly males (56, 65, 62 and 56%). Untreated control group comprised those patients whose owners decided on a minimal palliative intervention under our clinical surveillance.
Various breeds were represented among patients: mixed breed (41%), Pekingese (13%), Cocker Spaniel (11%), German Shepherd (9%), Doberman Pinscher (8%), Dachshund (5%) and others (12%).
All dogs (95% oral, 4% digital and 1% anal melanoma) were completely staged ( Table 1) . Most of the patients entering the study (67%) presented with stage III disease, as defined by WHO, with positive proximal lymph nodes. Only 11% of the patients bore lung metastases at the beginning of the trial.
The current study describes a combination of suicide gene therapy with immunotherapy in dogs with canine malignant melanoma as an alternative strategy that offers several advantages as discussed below.
The suicide gene system controlled the local disease in 47% of the cases The low response to the herpes simplex thymidine kinase (SG) observed in clinical trials may be due to low pro-drug concentration within tumors. 11, 12 We codelivered lipid-complexed SG with GCV, increasing the local concentration of the pro-drug that will be readily available for the expressed enzyme. In addition, our small plasmid vector (psCMV, 3.3 kb) contains a minimal proportion of sequences necessary for multiplication in E. coli, its lipofection efficiency being facilitated both in vitro and in vivo.
As far as we know, our data demonstrated for the first time in large animals the feasibility of lipid-complexed small plasmid DNA encoding SG therapy approach coadministrated with GCV to induce a strong local antitumor response. This was evidenced in those patients with objective responses (21/45) by a significant reduction (about 80%) in tumor size after five rounds of weekly SG treatment (Figure 1a) . SG produced, either alone or combined with cytokine-secreting xenogeneic cells, about 46% of objective responses, being higher in patients with smaller tumors (Figures 1b and c) . Such correlation was not seen in non-responder tumors (data not shown). The median duration of local response increased significantly from nearly 3 to 4 months in SG and combined treatment (CT), respectively ( Table 2 ).
The combined treatment significantly prolonged patient survival However, diminution of tumor mass in the SG group was necessary but not sufficient to improve remission and survival of surgery-treated (CX) control group (Table 3a) . In patients belonging to the CX or SG group, the prognosis still remained poor. The presence of highly heterogeneous residual tumor allowed many cells to evade immune attack. This was supported by the fact that dogs achieving local objective responses had longer overall survival times than non-responders (Table 3b) .
Conversely, CT resulted in a dramatic 2.3 augmentation in median survival with respect to UC and 1.95-fold with respect to CX or 1.7-fold with respect to SG (Kaplan-Meier analysis) ( Table 3a) .
Because of their advanced age, 26% (10/39) of deceased patients subjected to CT died by melanoma-unrelated causes. Most of the patients belonging to UC, CX, SG and CT groups (83, 91, 81 and 60% respectively) died or were humanely euthanized because of primary melanoma or metastasis progression as seen in Table 4 . None of the treatments significantly modified the causes of death pattern as analyzed by Fisher's exact test.
Local combined treatment induced immune cell infiltration
Repeated intra tumor injections of SG provided a key event for the success of immunotherapy: an immunostimulatory tumor microenvironment for immune effector cells to more efficiently kill residual tumor cells. 30 Cationic lipids and plasmid DNA immunostimulatory sequences might increase tumor immunogenicity. [31] [32] [33] In some patients, SG system alone or when combined with cytokine-producing xenogeneic cells produced inflammatory necrosis in 48 and 56% of dogs and a vitiligo-like tumor de-pigmentation at the sites of injection in 25 and 13% of SG and CT patients, respectively, suggesting some degree of immune response.
In addition, the coadministration of hIL-2 and hGM-CSF -producing xenogeneic cell, could convert the primary tumor destroyed by the SG into a tumor vaccine, 14, [17] [18] [19] as verified by the pronounced increase of immune cell infiltration after CT with respect to pretreatment biopsies (Figure 2) .
We chose the xenogeneic approach to assure secretion of cytokine in sufficient amounts for at least 2 or 3 days, avoiding the variability due to the inefficient gene transfer in areas presenting necrosis, edema or hemorrhage. On the other hand, colipofection of suicide and cytokine genes would dilute both gene products because of competition for the same expression machinery.
In previous experiments, we demonstrated that subcutaneous injection of 3 million hIL-2-secreting CHO cells to healthy immune-intact Balb/c mice weighing 30 g produced measurable seric hIL-2 for 72 h, with a peak of about 150 pg hIL-2 ml À1 at 48 h. Then, in dogs cells injected in the immunosuppressive intratumor environment could last the same, as or even longer than, in immunocompetent tissues. In addition, neither symptoms of acute xenograft rejection nor delayed-type hypersensitivity was observed during treatment. It is noteworthy that treatment with irradiated hIL-2-and hGM-CSF-producing xenogeneic cells alone was innocuous without any objective response on tumor burden. Only two of seven dogs displayed stable disease (with 40 and 20% of tumor reduction). The other dogs (5/7) developed tumor progression. The lack of effects of immunostimulatory molecules produced inside large tumors is consistent with the immunosuppressive environment created by tumor cells.
Local combined treatment controlled the systemic disease A very remarkable upshot was that local CT succeeded in controlling the systemic disease, as evidenced by suppression or delay in metastasis appearance as well as the significant increase of patients' overall survival and metastasis-free survival times (Tables 3 and 5) . As shown by Kaplan-Meier analysis, CT resulted in a remarkable increase in metastasis-free survival with respect to UC (412.4-fold), CX (43.8-fold) and SG (43.2-fold) groups (Table 3A) . It is noteworthy that more than 50% of the CT patients never developed metastasis. CT significantly enhanced the percentage of metastasis-free patients at the Abbreviations: CR, complete responses; OR, objective responses; PD, progressive disease; PR, partial responses; SD, stable disease.
Patients were clinically evaluated and treated as described in Figure 1 . Objective responses and stable disease were considered until they turned into progressive disease or death (whichever came first), while progressive disease duration was considered until the death of the patient. Values were derived from Kaplan-Meier analysis (plots not shown).
a CT vs SG objective responses: Po0.04, as calculated by log-rank test. (a) Overall survival: For Kaplan-Meier analysis, patients who died because of reasons unrelated to melanoma progression were censored as alive (no event) until the day of death. Metastasis-free survival: For Kaplan-Meier analysis, patients who have never developed metastases were censored as metastasisfree until the day of death. Both living and dead patients who developed metastases were considered.
(b) Overall survival values were derived from Kaplan-Meier analysis (plots not shown).
P-values were calculated by log-rank test. Combined therapy for canine malignant melanoma LME Finocchiaro et al end of the study (76%) compared to untreated, surgerytreated or SG-treated controls, as derived from Fisher's Exact test (Table 5 ). In addition, for those patients who developed lung and/or abdominal metastases, CT increased 2.8-and 2.2-fold the median metastasis-free survival lapse compared to UC and SG patients respectively, as derived from Kaplan-Meier analysis (Table 5 ). It is noteworthy that even though the proportion of stage I-II in the surgery control group was about twofold higher than in the other groups and this fact could have increased the number of metastasis-free patients compared with the untreated control group (Table 5) , surgical treatment did not significantly improve the survival rate (Table 3) . Undoubtedly, an extremely stimulating outcome was the complete remission of a pulmonary non-injected metastasis in a grade IV patient after 5 weekly local tumor CT, as shown in Figure 3 . The complete disappearance of a lung metastasis was maintained until the death of the dog 123 days after starting the treatment, because of the progression of the primary tumor. In addition, CT paused for about 3 months the lung metastasis progression of other three stage IV patients (data not shown).
Treatments were safe Repeated injections of DNA:DMRIE/DOPE lipoplexes of the SG system and cytokine-secreting xenogeneic cells into the tumor bed was safe, not allergenic and could be applied repetitively. Local necrosis, limited to the treatment site, was associated with tumor response. None of the treatments induced important local or systemic toxicity, organ dysfunction or fever in any treated patient. Fewer side effects were registered in some patients. They typically involved de-pigmentation (in 20% of cases) as well as edema (30%), swelling and itching (17%) at the injection places or mild flu-like symptoms 24-48 h after application (24%). There were no significant negative changes in complete blood counts or serum biochemical parameters during or at the completion of the study.
The combined treatment restored the quality of life of the patients To be accepted for clinical practice, any new cancer therapy should not only increase the survival lapse but also improve the quality of life. Contrary to other highly toxic therapies, our proposed treatment could contribute in both ways. In addition to the prolonged survival, it significantly restored the quality of life of the patients to M0, patients free of distant metastasis at the end of the treatment; M1, patients bearing distant metastases at the end of the treatment; M0-0, patients free of distant metastasis all along the treatment; M1-1, patients with distant metastases all along the treatment; M0-1, patients who developed distant metastasis during the treatment; M1-0, complete remission of lung metastasis.
Metastasis appearance times were derived from Kaplan-Meier analysis (plots not shown).
P-values were calculated by Fisher's exact (*) or log-rank (**) test.
the pre-disease state, as regularly reported by the owners: improving vigor (in 58%: 26/45 of cases), activity (71%: 32/45), mood (78%: 35/45), appetite (67%: 30/45), alert state (64%: 29/45), general welfare (69%: 31/45), clinical condition (73%: 33/45) and hematological parameters (60%: 27/45). This effect lasted as long as the disease was stable or regressing and it was abolished during relapse and disease progression. Occasionally, general welfare was periodically interrupted by 24-48 h transient flu-like mild symptoms that often followed treatment application. Recovery from surgery was generally slower (72-96 h), restoring the quality of life for a shorter period (see survival data in Table 3 ).
We can conclude that repeated injections of the suicide gene system and cytokine-secreting xenogeneic cells into the tumor bed could substantially control tumor growth, delay or prevent distant metastasis and significantly extend survival rate, with a consequent improvement in the quality of life of the patients.
Further studies are necessary to characterize this approach and to determine its suitability for human head and neck mucosal melanoma.
